Phase 2 Thyroid Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are between 2 and 25 years old (inclusive)
- You have been diagnosed with differentiated thyroid cancer, have had your thyroid removed, and have received appropriate treatment for any cancer spread to the lymph nodes in the neck
- You have lung nodules (small spots on the lungs) visible on a CT scan — either more than 10 solid nodules, or any number of nodules that are growing and appear to be cancer that has spread
- Your cancer has a specific change (called an "activating alteration") in a gene called RET, confirmed by a certified laboratory
- You are able to carry out daily activities at a reasonable level (confirm with trial site)
- Your blood counts are at acceptable levels — including white blood cells, platelets, and red blood cells
- Your kidneys are working at an acceptable level
- Your liver is working at an acceptable level, including acceptable levels of certain liver-related substances in your blood
- Your blood levels of potassium, calcium, and magnesium are normal (supplements are allowed to help reach this)
- If you are able to have children, you must agree to use highly effective birth control during treatment and for 6 months after the last dose
- If you could become pregnant, you must have a negative pregnancy test within 24 hours before starting treatment, and at least once a month while on treatment
Who may not be able to join:
- You have already had systemic (whole-body) treatment for thyroid cancer, including any RET-targeting drugs (note: previous radioactive iodine treatment is allowed)
- You are currently pregnant or breastfeeding
- You are currently taking certain medications that strongly affect how the body processes drugs (known as strong CYP3A4 inducers or inhibitors), or have taken them within 14 days before starting treatment (confirm specific medications with trial site)
- You have significant heart problems, have had a heart attack in the last 6 months, or have an abnormal heart rhythm reading on an ECG (a heart tracing test) above a certain level
- You have a condition that significantly affects your body's ability to absorb medicines taken by mouth
- You are taking any medication known to affect heart rhythm in a specific way (QTc prolongation — confirm with trial site)
- You have active bleeding or are at high risk of bleeding
- You have uncontrolled high blood pressure (though blood pressure medication to help control it is allowed)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Theodore Laetsch, MD, Children's Hospital of Philadelphia
Phone: 267-426-9343
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Number of patients with complete overall, pulmonary, structural, and biochemical response.; Number of patients who survive without progression of disease after 5 years following protocol treatment.; Proportion of all patients enrolled who show increased radioactive iodine avidity at 6 months following selpercatinib monotherapy.; The incidence of adverse events and dose limiting toxicity with the combination of selpercatinib and 131I therapy, graded according to CTCAE v5.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.